Chemical Name: 4-[4-(5-Benzofuranyl)phenyl]-5-[[(3S)-1-(cyclopropylcarbonyl)-3-pyrrolidinyl]methyl]-2,4-dihydro-3H-1,2,4-triazol-3-one
Biological ActivityGSK 2194069 is a potent human fatty acid synthase (hFASN) inhibitor (IC50 = 7.7 nM); inhibits hFAS β-ketoacyl reductase activity. Inhibits lipid synthesis and attenuates proliferation of A549 non-small-cell lung cancer cells (EC50 = 15 nM) in vitro. GSK 2194069 also inhibits infection by SARS-CoV-2 (EC50 = 0.9 nM) in vitro.
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site.
Hardwicke et al.
Citations for GSK 2194069
The citations listed below are publications that use Tocris products. Selected citations for GSK 2194069 include:
4 Citations: Showing 1 - 4
Cancer cells depend on environmental lipids for proliferation when electron acceptors are limited.
Authors: Evan C Et al.
Nat Metab 2022;4:711-723
Low glycaemic diets alter lipid metabolism to influence tumour growth.
Authors: Lien Et al.
Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication.
Authors: Chu Et al.
SREBP1-dependent de novo fatty acid synthesis gene expression is elevated in malignant melanoma and represents a cellular survival trait.
Authors: Wu and Näär
Sci Rep 2019;9:10369
No product specific FAQs exist for this product, however you mayView all Small Molecule FAQs
Reviews for GSK 2194069
There are currently no reviews for this product. Be the first to review GSK 2194069 and earn rewards!
Have you used GSK 2194069?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image